USV Launches Empagliflozin Combos for Diabetes Care in India

USV, an Indian multinational healthcare company, has launched Xenia (empagliflozin and its combinations), a leading SGLT2 inhibitor, for glycaemic control, heart failure and chronic kidney care in people with type 2 diabetes.  This launch strengthens USV’s presence in the Rs. 1,100 crore SGLT2i market and reinforces its leadership in oral anti-diabetes care.
 
USV has introduced Xenia (empagliflozin 10 mg & 25 mg), Xenia M (empagliflozin 12.5 mg + metformin 500 mg IR/1000 mg ER), and Xenia ST (empagliflozin 25 mg + sitagliptin 100 mg).
 
These combinations offer flexible dosing, reduced pill burden, and improved access to modern therapy, enabling early treatment to reduce diabetes complications and mortality.
 
Commenting on the launch, Prashant Tewari, managing director, USV said: ""India has over 101 million people with type 2 diabetes and 136 million with prediabetes. With Xenia, we aim to expand access to modern diabetes care while reinforcing our leadership in the segment. USV remains committed to delivering affordable, high-quality therapies for better patient outcomes.""
 
With the loss of exclusivity, empagliflozin and its combinations are now available at one-fifth the cost, enhancing affordability. USV’s extensive reach across metros, Tier I, II & III cities, corporate hospitals, and e-pharmacies ensures Xenia's accessibility nationwide, including rural areas.
 
Established in 1961, USV Private Limited is a leading Indian multinational healthcare company with a presence in 65+ countries. In India, USV holds the #1 position by prescriptions in the oral anti-diabetic and cardiology markets. Its global portfolio includes APIs, generics, branded generics, peptides, and biosimilars.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!